Colossal Biosciences logo
Biotech/Pharma
Other
Climate/Energy

Colossal Biosciences

Reviving extinct species through genetics

CORE INFO

$435M
Total Funding
Series C
Round
2021
Founded
170
Team Size
Dallas, Texas, United States
Headquarters

Colossal Biosciences is a biotechnology company focused on using genetic engineering to revive extinct species, such as the woolly mammoth and the dodo, with the aim of restoring biodiversity and enhancing conservation efforts.

  • Series C funding round raised $200 million, bringing the company's valuation to $10.2 billion.techcrunch.com
  • Bloomberg reported on Colossal's ambitious timeline to produce a woolly mammoth by 2028.bloomberg.com

WHY WE WOULD WORK AT COLOSSAL BIOSCIENCES

Pioneering De-Extinction

Join a groundbreaking mission to revive extinct species like the woolly mammoth and dodo, utilizing cutting-edge CRISPR gene-editing technology to combat biodiversity loss.

Impactful Conservation Efforts

Contribute to global conservation initiatives aimed at restoring ecological balance and enhancing biodiversity through innovative genetic solutions.

Strong Financial Backing

Be part of a rapidly growing company valued at $10.2 billion, backed by significant funding, including a recent $200 million Series C round.

Collaborate with Experts

Work alongside renowned scientists and industry leaders, including Harvard geneticist Dr. George Church, in a dynamic and intellectually stimulating environment.

Recognized Industry Leader

Join a company recognized as a Technology Pioneer by the World Economic Forum and included in Time's 100 Most Influential Companies of 2023.

Sustainable Future Focus

Engage in projects that not only aim to bring back extinct species but also promote environmental sustainability and responsible stewardship of our planet.

MARKET AND TRACTION

TOTAL FUNDING

✦ KEY METRIC
  • Colossal Biosciences has raised a total of $435 million in funding as of January 2025.

  • The most recent funding round was a Series C, where the company raised $200 million, bringing its valuation to $10.2 billion.
  • TEAM SIZE

    ✦ KEY METRIC
  • As of 2025, Colossal Biosciences has approximately 170 employees.

  • The team comprises experts in biotechnology, genetics, and conservation biology, driving the company's ambitious de-extinction projects.
  • NOTABLE ACHIEVEMENTS

  • Colossal Biosciences was recognized as a Technology Pioneer by the World Economic Forum in 2022.

  • The company was included in Time magazine's list of the 100 Most Influential Companies in 2023, highlighting its impact in the field of biotechnology and conservation.
  • MARKET POSITION

  • Colossal Biosciences is positioned as a leader in the biotechnology sector focused on de-extinction and conservation efforts.

  • The company aims to address the global extinction crisis by reviving extinct species and restoring biodiversity, setting it apart from traditional conservation methods.
  • GROWTH TACTICS

  • The company utilizes advanced CRISPR gene-editing technology to facilitate its de-extinction projects.

  • Colossal is actively expanding its portfolio of species targeted for revival, including the woolly mammoth, thylacine, and bluebuck, to enhance its conservation impact.
  • PRODUCT AND TECH

    CRISPR Gene-Editing

    Colossal Biosciences utilizes CRISPR gene-editing technology to manipulate the genetic material of extinct species, enabling the potential revival of animals like the woolly mammoth and dodo. This advanced technique is crucial for precise genetic modifications necessary for de-extinction efforts.

    Reproductive Techniques

    The company employs innovative reproductive techniques to facilitate the gestation and birth of revived species, ensuring that genetic modifications lead to viable offspring. These methods are essential for successfully reintroducing extinct species into their natural habitats.

    De-Extinction Projects

    Colossal is actively engaged in de-extinction projects targeting species such as the woolly mammoth, thylacine, and bluebuck, aiming to restore biodiversity and ecological balance. These projects represent a groundbreaking approach to conservation and species restoration.

    Artificial Egg Incubation

    In a significant advancement for avian de-extinction, Colossal has developed artificial egg incubation methods, successfully hatching chicks using 3D-printed artificial eggs. This technology is pivotal for reviving bird species that have gone extinct.

    Conservation Biology Initiatives

    Colossal's initiatives extend beyond de-extinction, focusing on enhancing conservation efforts through genetic technologies to mitigate biodiversity loss. These initiatives aim to promote environmental sustainability and restore ecological integrity.

    COMPANY CULTURE

    Values

  • Commitment to biodiversity restoration

  • Innovation through advanced genetic technologies

  • Collaboration in scientific research and conservation efforts

  • Ethical responsibility in de-extinction practices

  • Passion for environmental sustainability
  • Operating Principles

  • Emphasis on teamwork and interdisciplinary collaboration

  • Focus on transparency in research and development

  • Continuous improvement through feedback and adaptation

  • Encouragement of creative problem-solving approaches

  • Dedication to scientific integrity and ethical standards
  • Benefits

  • Opportunities for professional development and growth

  • Engaging work environment that fosters creativity

  • Competitive compensation and benefits packages

  • Participation in groundbreaking conservation projects

  • Supportive culture that values employee well-being
  • Learning & Growth

  • Access to cutting-edge research and technology

  • Regular training and workshops on genetic engineering

  • Mentorship programs with industry leaders

  • Encouragement of continuous learning and curiosity

  • Opportunities to attend conferences and share knowledge
  • Team Cadence

  • Regular team meetings to align on goals and progress

  • Collaborative project-based work structure

  • Open communication channels for idea sharing

  • Flexible work arrangements to promote work-life balance

  • Celebrations of team achievements and milestones
  • HIRING SIGNAL

    0
    Open roles on their careers page
    Snapshot via live ATS poll
    —
    Net new roles in the last 90 days
    Available once weekly history accrues
    90-Day VelocityV2 · BACKFILL
    Trend builds weekly as historical rows accrue
    SourcesGreenhouseLeverAshbyWorkableSmartRecruitersRipplingRecruiteeFallback · Wellfound, YC Work-at-a-Startup, careers-page scrape

    KEY COMPANY ANNOUNCEMENTS

    Filter
    15 announcements · ranked by importance
    Jan 15, 2025FUNDINGColossal Biosciences raises $200M at $10.2B valu. to bring back woolly mammothstechcrunch.com
    Jul 20, 2026FUNDINGColossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation | TechCrunchtechcrunch.com
    Jan 31, 2023FUNDINGColossal Biosciences Secures $150M Series B and Announces Plan to De-Extinct the Iconic Dodobusinesswire.com
    Mar 9, 2022FUNDINGA Colossal $60 million Series Acolossal.com
    Aug 15, 2022FOUNDER PROFILEBringing Back the Woolly Mammoth | The New Yorkernewyorker.com
    Apr 14, 2025PRESSThe Dire Wolf Is Back | The New Yorkernewyorker.com
    Sep 1, 2021ESSAYIs Colossal Biosciences a Real Company?colossal.com
    May 19, 2026MILESTONEColossal Biosciences Artificial Egg Hatches 26 Chickens in Breakthrough Step Toward Dodo and Moa De-Extinctioncolossal.com
    Jun 30, 2026MILESTONEColossal Biosciences and the U.S. Fish and Wildlife Service Partner to Preserve the Genetics of More Than 2,300 Endangered Speciescolossal.com
    Jul 13, 2026MILESTONEHow Colossal’s Thylacine De-Extinction Technology Is Now Helping a Living Marsupialcolossal.com
    Jun 15, 2026MILESTONEColossal Biosciences’ Screwworm Gene Drive: A Plan to Eliminate the Flesh-Eating Parasite in the UScolossal.com
    Dec 17, 2025FUNDINGColossal Foundation Raises Extra $50M for Conservationcolossal.com
    Oct 1, 2024MILESTONEColossal Launches The Colossal Foundationmarkets.financialcontent.com
    Jul 13, 2026CUSTOMER WINColossal Foundation and University of Tasmania Partner to Combat Devil Facial Tumor Diseasecolossal.com
    Jan 1, 2022INTERVIEWMaking more mammoths with Ben Lamm from Colossaltechcrunch.com